Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial
ConclusionThis study indicates that amisulpride augmentation therapy has important clinical significance for treating CTRS to improve clinical symptoms and cognitive function with tolerability and safety.Trial registration Clinicaltrials.gov identifier- NCT03652974. Registered August 31, 2018,https://clinicaltrials.gov/ct2/show/NCT03652974
Source: Military Medical Research - Category: International Medicine & Public Health Source Type: research
More News: Brain | Electrocardiogram | International Medicine & Public Health | Laboratory Medicine | Neurology | Psychiatry | Research | Schizophrenia | Study